Navigation Links
InEnTec Medical Services LLC Cancels Permits to Build a Waste Recycle and Power Production Facility Near Red Bluff, California
Date:6/13/2008

BEND, Ore., June 13 /PRNewswire/ -- InEnTec Medical Services LLC, a subsidiary of InEnTec LLC, today announced its plans to cancel its project to construct a Plasma Enhanced Melter ("PEMTM) and power generation facility near the city of Red Bluff in Tehama County, California. The facility would have recycled medical waste and other non-hazardous waste materials into clean electric energy. Citing changing business strategies and market conditions, the company will focus its efforts on advancing several other regional opportunities in the United States to bring environmentally friendly and cost-effective solutions to the problems of waste disposal and the need for clean fuels and energy.

"We are disappointed that Tehama County will not have the opportunity to establish itself as a leader in bringing an environmentally sound solution to the disposal of medical waste," said Jeff Surma, President and Chief Executive Officer of InEnTec LLC. "When our company started this project over three years ago, our focus was on developing smaller scale systems geared toward niche waste streams such as medical waste. Since that time we have evolved our technology to a scale that now makes economic sense for all waste streams, including municipal solid waste, or everyday trash. It is our firm belief and our hope that someday all communities, including Tehama County, will use technologies such as ours to reuse these waste materials to produce other products such as ethanol or methanol, which would be more environmentally responsible than stockpiling our garbage in landfills," Surma said. "We'd like to thank the Tehama County Planning Commission and the staff of the Tehama County Air Pollution Control District for their professionalism and courtesy throughout the process, and we look forward to the possibility of doing business in Tehama County in the future."

InEnTec Medical Services currently has both a land use permit issued by the Tehama County Planning Commissi
'/>"/>

SOURCE InEnTec Medical Services LLC
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Rising Medical Solutions Chooses Bank of America to Bring Enhanced Cash Management and Provider Payment Solutions to the Marketplace
2. Hoana Medical, Inc. Awarded a Federal Supply Contract Through the U.S. Department of Veteran Affairs
3. Twenty of Americas Most Promising Scientists Selected as 2008 Pew Scholars in the Biomedical Sciences
4. Medical research on ice
5. hakia Boosts Health and Medical Search Capabilities with PubMed
6. Rochester Medical Honored by Premier Healthcare Alliance for Exceeding Performance Expectations
7. China Sky One Medical, Inc. to Acquire Peng Lai Jin Chuang Company
8. China Medical Technologies Reports Fourth Quarter and Full Year Financial Results
9. Fresenius Medical Care Supports Chinese Earthquake Victims
10. Sysmex America to Enable Prolonged Hematology Instrument Uptime for Hagerstown Medical Laboratory With 1,000th SNCS Activation
11. Nonin(R) Medical Announces Strategic Relationship With Microsoft and its Microsoft HealthVault Platform
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Dynatronics Receives 180-Day NASDAQ Extension 2Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline 2YAI NIPD Board of Trustees Elects Eliot Green Chair and Sheldon Kwiat Vice Chair 51695 1YAI NIPD Board of Trustees Elects Eliot Green Chair and Sheldon Kwiat Vice Chair 51695 2YAI NIPD Board of Trustees Elects Eliot Green Chair and Sheldon Kwiat Vice Chair 51695 3OH2 Medical Spa Achieves the First U S LEED 28R 29 Certification for a Medical Commercial Interior 51691 1OH2 Medical Spa Achieves the First U S LEED 28R 29 Certification for a Medical Commercial Interior 51691 2Fitness Might Limit Strokes Impact 51687 1Fitness Might Limit Strokes Impact 51687 2